Northern Trust Corp Sells 31,637 Shares of Insulet Corporation $PODD

Key Points

• Northern Trust Corp reduced its holdings in Insulet Corporation by 4.3% during the first quarter, owning approximately 1.01% of the company with shares valued at $185.7 million after selling 31,637 shares.
• GAMMA Investing LLC dramatically increased its position in Insulet by 27,298.6%, acquiring 664,141 shares now valued at approximately $1.74 billion, after buying an additional 661,717 shares.
• The company reported $1.17 EPS for its last quarter, exceeding the analyst estimate of $0.92, with a 32.9% year-over-year revenue growth of $649.1 million.

Northern Trust Corp decreased its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 4.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 707,174 shares of the medical instruments supplier's stock after selling 31,637 shares during the quarter. Northern Trust Corp owned approximately 1.01% of Insulet worth $185,711,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Brooklyn Investment Group lifted its holdings in Insulet by 7.0% in the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock valued at $209,000 after acquiring an additional 52 shares during the period. Algert Global LLC lifted its holdings in Insulet by 10.2% in the first quarter. Algert Global LLC now owns 10,450 shares of the medical instruments supplier's stock valued at $2,744,000 after acquiring an additional 968 shares during the period. Raymond James Financial Inc. lifted its holdings in Insulet by 31.5% in the first quarter. Raymond James Financial Inc. now owns 349,700 shares of the medical instruments supplier's stock valued at $91,835,000 after acquiring an additional 83,743 shares during the period. Alliance Wealth Advisors LLC UT lifted its holdings in Insulet by 2.3% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,337 shares of the medical instruments supplier's stock valued at $876,000 after acquiring an additional 74 shares during the period. Finally, American Century Companies Inc. lifted its holdings in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after acquiring an additional 297,734 shares during the period.

Insulet Price Performance

PODD traded up $2.92 on Friday, hitting $330.77. 499,504 shares of the company's stock traded hands, compared to its average volume of 703,757. The company's 50 day simple moving average is $300.94 and its 200-day simple moving average is $285.90. The firm has a market cap of $23.28 billion, a price-to-earnings ratio of 100.54, a P/E/G ratio of 2.77 and a beta of 1.35. Insulet Corporation has a one year low of $180.31 and a one year high of $334.18. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the company earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Truist Financial assumed coverage on Insulet in a research note on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective on the stock. Barclays raised their price objective on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research note on Thursday. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Finally, Citigroup reaffirmed a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Sixteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $332.71.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.